|
News
-
01.29.2024Perkins Coie’s ECVC Practice Advises weavix in $23.6M Series B Funding RoundPress ReleasesPerkins Coie is pleased to have advised weavix in a $26.3 million Series B funding round led by global software investor Insight Partners. Four More Capital, The Friedkin Group, and Perkins Coie also participated in the funding round.
-
11.09.2023Perkins Coie Congratulates 22 New PartnersPress ReleasesPerkins Coie is pleased to announce that 22 counsel and senior counsel have been promoted to partner effective January 1, 2024.
-
04.20.2023Perkins Coie’s ECVC Practice Advises Point72 Ventures in Lexion’s $20M Series B FundraisingPress ReleasesPerkins Coie is pleased to have advised Point72 Ventures, a global venture capital fund, in Lexion’s $20 million Series B funding round.
-
08.18.2022Best Lawyers® 2023 Recognizes 403 Perkins Coie AttorneysPress ReleasesPerkins Coie is proud to announce that 403 of its attorneys have been recognized by Best Lawyers® 2023. A total of 279 attorneys were selected by their peers for inclusion in the 2023 edition of The Best Lawyers in America® and 124 attorneys were selected for inclusion in the 2023 edition of Best Lawyers: Ones to Watch.
-
02.09.2022Perkins Coie Represents MariaDB in Combination With Angel Pond Holdings to Become a Publicly Traded CompanyPress ReleasesPerkins Coie is pleased to represent MariaDB Corporation Ab, as it has entered into a business combination agreement to become a publicly listed company on the New York Stock Exchange (NYSE) with Angel Pond Holdings Corporation, a special purpose acquisition company.
-
12.06.2021Perkins Coie Announces 2022 Counsel PromotionsPress ReleasesPerkins Coie is pleased to announce that 47 attorneys have been promoted to the firm’s counsel position, effective January 1, 2022.
-
06.04.2021Perkins Coie Represents Synchron in Series B $40 Million Funding Round with Khosla VenturesPress ReleasesPerkins Coie is pleased to have represented Synchron, a brain interface platform company, in its Series B $40 million round of financing led by Silicon Valley venture capital fund Khosla Ventures.
-
12.18.2020Perkins Coie Represents BlackSwan Vascular in Strategic Investment by Sirtex MedicalPress ReleasesPerkins Coie is pleased to announce that it represented BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, in a Series B financing as part of a strategic investment by Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies.
